Open AccessThis article is
- freely available
Antitumor Virotherapy by Attenuated Measles Virus (MV)
INSERM, UMR892, Nantes, F-44000, France
CNRS, UMR6299, Nantes, F-44000, France
Université de Nantes, Nantes, F-44000, France
CNRS, URA3015, Institut Pasteur, Unité de Génomique Virale et Vaccination, Paris, 75015, France
* Author to whom correspondence should be addressed.
Received: 4 February 2013; in revised form: 28 February 2013 / Accepted: 5 March 2013 / Published: 28 March 2013
Abstract: Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the complement system and is frequently overexpressed by cancer cells to escape lysis by the complement system. MV exhibits oncolytic properties in many cancer types in vitro, and in mouse models. Phase I clinical trials using MV are currently underway. Here, we review the state of this therapeutic approach, with a focus on the effects of MV on the antitumor immune response.
Keywords: antitumor virotherapy; measles virus vaccine; dendritic cells; tumor antigen; clinical trial; vaccine
Citations to this Article
Cite This Article
MDPI and ACS Style
Guillerme, J.-B.; Gregoire, M.; Tangy, F.; Fonteneau, J.-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology 2013, 2, 587-602.
Guillerme J-B, Gregoire M, Tangy F, Fonteneau J-F. Antitumor Virotherapy by Attenuated Measles Virus (MV). Biology. 2013; 2(2):587-602.
Guillerme, Jean-Baptiste; Gregoire, Marc; Tangy, Frédéric; Fonteneau, Jean-François. 2013. "Antitumor Virotherapy by Attenuated Measles Virus (MV)." Biology 2, no. 2: 587-602.